Preoperative intravenous iron supplementation was not superior to placebo to reduce the need for blood transfusion or mortality when administered to patients with anemia 10–42 days before elective major abdominal surgery.
Long-term follow-up of the LIR!C trial (laparoscopic ileocecal resection vs. infliximab for terminal ileitis in Crohn’s disease)
Long-term analyses of patients enclosed in the LIR!C trial support the notion that laparoscopic ileocecal resection is a reasonable treatment option for ileocecal Crohn’s disease. A considerable proportion of patients who underwent surgery did not require additional Crohn’s disease-related medications or only primary prophylaxis of recurrence. In contrast, most of the patients treated with infliximab required long-term therapy with biologics or escalation of therapies and approx. half of the patients ultimately required surgery.
In a current database evaluation, approx. 2% of acute liver failure cases occurred during pregnancy. Pregnancy-associated liver diseases (acute fatty liver of pregnancy or HELLP syndrome with hemolysis, elevated liver enzymes and low platelets) caused only about half of the cases. Prognosis of acute liver failure in pregnancy is still poor: In the current analysis, 11 of 70 patients (16%) required liver transplantation and 8 patients (11%) died.
A recent retrospective cohort study confirms that patients with hepatic steatosis and persistently normal alanine aminotransferase do not have an increased risk of liver cirrhosis and hepatocellular carcinoma. Thus, these patients probably do not require close monitoring for liver outcomes.
Oesophagus Stomach Duodenum
Time-restricted eating, in the absence of other interventions, was not more effective in weight loss than conventional eating (3 structured meals throughout the day) in a randomized clinical trial involving 116 participants with overweight and obesity.
The anti-Siglec-8 antibody AK002 significantly reduced gastrointestinal eosinophils and clinical symptoms in a phase 2 trial.
According to a retrospective analysis of 878 patients, famotidine use in hospitalized patients with COVID-19 was associated with a lower risk of mortality, lower risk of combined outcome of mortality and intubation, and lower serum markers for severe inflammation.
The multikinase inhibitor surufatinib significantly improved progression-free survival and had an acceptable safety profile in patients with advanced pancreatic NETs in a Chinese phase 3 trial.